1 3 glucan/nausea

Lyen an sove nan clipboard la

AtikEsè klinikPatant

Chwazi kalite sòt

13 rezilta yo

Candida meningitis in an immunocompetent patient detected through (1→3)-beta-d-glucan.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A 44-year-old female presented with a 3-month history of headache, dizziness, nausea, and vomiting. Her past medical history was significant for long-standing intravenous drug abuse. Shortly after admission, the patient became hypertensive and febrile, with fever as high as 38.8°C. The lumbar

Two randomized, double-blind, placebo-controlled, dose-escalation phase 1 studies evaluating BTH1677, a 1, 3-1,6 beta glucan pathogen associated molecular pattern, in healthy volunteer subjects.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND BTH1677 is a beta glucan pathogen associated molecular pattern (PAMP) currently being investigated as a novel cancer therapy. Here, the initial safety and pharmacokinetic (PK) results of BTH1677 in healthy subjects are reported. METHODS In the Phase 1a single-dosing study, subjects were

[Anidulafungin].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Anidulafungin is a new echinocandin antifungal agent recently approved in Spain by the Spanish Drug Agency. As other echinocandins, it inhibits a selective target, 1,3- beta-D-glucan synthesis, a major structural component of the fungal cell wall which is not present in mammalian cells, this

Caspofungin: an echinocandin antifungal agent.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND The mainstays of treatment for nosocomial fungal infections have been amphotericin B and azole derivatives. Caspofungin acetate is a new echinocandin antifungal agent with a mechanism of action that targets a structural component of the fungal cell wall. OBJECTIVE This article describes

A Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Active Hexose Correlated Compound (AHCC) is an extract of Lentinula edodes of the basidiomycete family of fungi rich in alpha glucans. AHCC has been used for many years as a dietary supplement to enhance the immune system and in clinical trials as an adjunctive treatment in Hepatocellular cancer.

[A case of pneumocystis pneumonia during chemotherapy for gastric cancer].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

We report a death case of a man in his sixties with pneumocystis pneumonia during chemotherapy for gastric cancer. He was diagnosed with cStage IIIB (T4a, N2, H0, P0, M0). Because of bulky N2, systemic chemotherapy of S-1 and CDDP was performed from April 2009. But no reductions were noted after 2

A case report of purulent pericarditis caused by Candida albicans: Delayed complication forty-years after esophageal surgery.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Candida pericarditis is a rare condition with high mortality. Risk factors include thoracic surgery and immunosuppression. We report a case of candida pericarditis which developed forty-years after esophageal reconstruction surgery. UNASSIGNED A 42-year-old female presented with nausea,

[Anidulafungin: a new therapeutic approach in antifungal therapy. Pharmacology of anidulafungin].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Anidulafungin is a new echinocandin antifungal agent which inhibits beta-1,3-D-glucan synthase and disrupts fungal cell-wall synthesis. It has marked antifungal activity against Candida spp. and Aspergillus spp., including amphotericin B and triazole resistant strains. Due to the limited oral

Caspofungin.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Caspofungin is the first in a new class of antifungal agents, the glucan synthesis inhibitors, that interfere with fungal cell wall synthesis. Caspofungin exhibited in vitro and in vivo efficacy against a wide range of fungi and yeasts including Aspergillus and Candida species. A complete or partial

Efficacy of caspofungin combined with clindamycin for Pneumocystis jirovecii pneumonia in a systemic lupus erythematosus patient: A case report and literature review.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Pneumocystis jirovecii pneumonia (PCP) is an opportunistic infection with a difficult diagnosis, rapid progression, high mortality rate and poor prognosis. The primary treatment and prevention of PCP is trimethoprim/sulfamethoxazole (TMP/SMZ). However, there are many cases of

Anidulafungin.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Anidulafungin is a novel antifungal agent which, like other echinocandins, inhibits beta-(1,3)-D-glucan synthase and disrupts fungal cell-wall synthesis. It has marked antifungal activity against a broad spectrum of Candida spp. and Aspergillus spp., including amphotericin B- and triazole-resistant

Micafungin use in children.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Invasive fungal infections (IFIs) are one of the major reasons for morbidity and mortality in immunocompromised children. The majority of IFIs are caused by Candida and Aspergillus species. Early diagnosis and prompt initiation of appropriate antifungal therapy is essential for favorable outcome.

[Caspofungin: mode of action and therapeutic applications].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

METHODS Since the last two decades, the incidence of invasive fungal infections has drastically increased. It becomes urgent to enlarge the panel of antifungal drugs with more potent activity and less toxicity. Since the target of all previously available antifungal agents is the synthesis of

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye